JP2017508724A5 - - Google Patents

Download PDF

Info

Publication number
JP2017508724A5
JP2017508724A5 JP2016546449A JP2016546449A JP2017508724A5 JP 2017508724 A5 JP2017508724 A5 JP 2017508724A5 JP 2016546449 A JP2016546449 A JP 2016546449A JP 2016546449 A JP2016546449 A JP 2016546449A JP 2017508724 A5 JP2017508724 A5 JP 2017508724A5
Authority
JP
Japan
Prior art keywords
nanoparticle composition
drug delivery
payload
polypeptide
delivery polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016546449A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017508724A (ja
JP6608370B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/011870 external-priority patent/WO2015109264A1/en
Publication of JP2017508724A publication Critical patent/JP2017508724A/ja
Publication of JP2017508724A5 publication Critical patent/JP2017508724A5/ja
Priority to JP2019192818A priority Critical patent/JP7665282B2/ja
Application granted granted Critical
Publication of JP6608370B2 publication Critical patent/JP6608370B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016546449A 2014-01-17 2015-01-16 受容体標的化構築物およびその使用 Active JP6608370B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2019192818A JP7665282B2 (ja) 2014-01-17 2019-10-23 受容体標的化構築物およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461928903P 2014-01-17 2014-01-17
US61/928,903 2014-01-17
PCT/US2015/011870 WO2015109264A1 (en) 2014-01-17 2015-01-16 Receptor targeting constructs and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019192818A Division JP7665282B2 (ja) 2014-01-17 2019-10-23 受容体標的化構築物およびその使用

Publications (3)

Publication Number Publication Date
JP2017508724A JP2017508724A (ja) 2017-03-30
JP2017508724A5 true JP2017508724A5 (enExample) 2018-03-01
JP6608370B2 JP6608370B2 (ja) 2019-11-20

Family

ID=53543519

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016546449A Active JP6608370B2 (ja) 2014-01-17 2015-01-16 受容体標的化構築物およびその使用
JP2019192818A Active JP7665282B2 (ja) 2014-01-17 2019-10-23 受容体標的化構築物およびその使用
JP2024128996A Pending JP2024156895A (ja) 2014-01-17 2024-08-05 受容体標的化構築物およびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019192818A Active JP7665282B2 (ja) 2014-01-17 2019-10-23 受容体標的化構築物およびその使用
JP2024128996A Pending JP2024156895A (ja) 2014-01-17 2024-08-05 受容体標的化構築物およびその使用

Country Status (12)

Country Link
US (3) US10183078B2 (enExample)
EP (2) EP3791889B1 (enExample)
JP (3) JP6608370B2 (enExample)
KR (1) KR102434541B1 (enExample)
CN (1) CN106413738B (enExample)
AU (2) AU2015206271B2 (enExample)
BR (1) BR112016016202A2 (enExample)
IL (1) IL246668B (enExample)
MX (1) MX381016B (enExample)
RU (1) RU2682335C2 (enExample)
WO (1) WO2015109264A1 (enExample)
ZA (1) ZA201605237B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9078927B2 (en) 2007-07-06 2015-07-14 Cedars-Sinai Medical Center Self-assembling complex for targeting chemical agents to cells
WO2010085665A2 (en) 2009-01-23 2010-07-29 Cedars-Sinai Medical Center Targeted delivery system
PL2880160T3 (pl) 2012-08-03 2019-03-29 Cedars-Sinai Medical Center Izolowanie wzmacniających transport mutantów białka dostarczającego lek
ES2791043T3 (es) 2013-05-08 2020-10-30 Cedars Sinai Medical Center Orientación de corroles para toxicidad tumoral e IRM
EP3791889B1 (en) 2014-01-17 2024-02-21 Cedars-Sinai Medical Center C-met receptor targeting constructs and uses thereof
CA2943297A1 (en) 2014-04-04 2015-10-08 Cedars-Sinai Medical Center Targeting trastuzumab-resistant her2+ breast cancer with a her3-targeting nanoparticle
US20190240344A1 (en) * 2016-10-03 2019-08-08 Eos Biosciences, Inc. Functional rna and small-molecule drug therapeutic complexes and nanoparticle delivery vehicles
CN108865147B (zh) * 2018-06-01 2021-05-18 福州大学 一种埃罗替尼保护的铂银纳米簇及其制备方法
RU2688422C1 (ru) * 2018-06-07 2019-05-21 Светлана Александровна Ермолаева Рекомбинантный интерналин В 321, полученный с помощью штамма Escherichia coli
WO2020028562A1 (en) * 2018-07-31 2020-02-06 Loma Linda University Snail sirna-loaded mesoporous silica nanoparticles
AU2021239080A1 (en) 2020-03-15 2022-09-29 Nanocarry Therapeutics Ltd. Nano-delivery system and therapeutic and diagnostic use thereof
CN119868271A (zh) * 2024-12-30 2025-04-25 沈阳药科大学 一种化疗药物与免疫刺激剂共递送的功能性聚合物胶束及其制备方法和应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
CA1294215C (en) 1986-10-27 1992-01-14 Ze'ev Shaked Pharmaceutical compositions of recombinant beta-interferon and formulation processes
CA1292686C (en) 1986-10-27 1991-12-03 Ze'ev Shaked Pharmaceutical compositions of recombinant interleukin-2 and formulation process
US5391723A (en) 1989-05-31 1995-02-21 Neorx Corporation Oligonucleotide conjugates
US5587384A (en) 1994-02-04 1996-12-24 The Johns Hopkins University Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US6333396B1 (en) 1998-10-20 2001-12-25 Enzon, Inc. Method for targeted delivery of nucleic acids
CA2391534A1 (en) 1999-11-15 2001-05-25 Drug Innovation & Design, Inc. Selective cellular targeting: multifunctional delivery vehicles
US6855135B2 (en) 2000-11-29 2005-02-15 Hill-Rom Services, Inc. Vacuum therapy and cleansing dressing for wounds
US20030170826A1 (en) 2001-02-02 2003-09-11 Peter Rabinovich Peptides for facilitating composite receptor expression and translocation of macromolecules
WO2002094318A1 (en) 2001-05-18 2002-11-28 University Of Southern California Vector for targeted delivery to cells
EP1411927B1 (en) 2001-07-02 2010-06-30 Technion Research and Development Foundation Ltd. Method for the preparation of selectively-substituted corroles and new substituted corroles
SE0201863D0 (en) 2002-06-18 2002-06-18 Cepep Ab Cell penetrating peptides
EP1374812A1 (en) 2002-06-28 2004-01-02 Biopol Co., Ltd. Multilayered microporous foam dressing and method for manufacturing the same
US7329638B2 (en) 2003-04-30 2008-02-12 The Regents Of The University Of Michigan Drug delivery compositions
US7205387B2 (en) 2003-08-28 2007-04-17 Agency For Science, Technology And Research Recombinant polypeptide useful for neurotrophin receptor mediated gene delivery and as neurotrophin agonist
US20050096502A1 (en) 2003-10-29 2005-05-05 Khalili Theodore M. Robotic surgical device
WO2005117928A1 (en) 2004-05-30 2005-12-15 Cemines, Inc. Compositions and methods for the treatment of skin cancer
US8057821B2 (en) 2004-11-03 2011-11-15 Egen, Inc. Biodegradable cross-linked cationic multi-block copolymers for gene delivery and methods of making thereof
US20060217308A1 (en) * 2005-03-10 2006-09-28 Pascale Cossart Compositions for the treatment of tumor pathologies, comprising internalin B (ln1B) of Listeria monocytogene protein or a fragment thereof
US8080534B2 (en) 2005-10-14 2011-12-20 Phigenix, Inc Targeting PAX2 for the treatment of breast cancer
US20110052697A1 (en) 2006-05-17 2011-03-03 Gwangju Institute Of Science & Technology Aptamer-Directed Drug Delivery
US9078927B2 (en) 2007-07-06 2015-07-14 Cedars-Sinai Medical Center Self-assembling complex for targeting chemical agents to cells
AU2008293376B2 (en) 2007-08-28 2013-07-11 Technion Research & Development Foundation Ltd. Transition metal complexes of corroles for preventing cardiovascular diseases or disorders
US8541568B2 (en) 2008-05-24 2013-09-24 Hai Yan Compositions and methods using siRNA molecules for treatment of gliomas
US10036099B2 (en) 2008-08-07 2018-07-31 Slt Technologies, Inc. Process for large-scale ammonothermal manufacturing of gallium nitride boules
US9012622B2 (en) 2008-12-31 2015-04-21 Patrick Y. Lu Compositions and methods using siRNA molecules and siRNA cocktails for the treatment of breast cancer
WO2010085665A2 (en) 2009-01-23 2010-07-29 Cedars-Sinai Medical Center Targeted delivery system
JP2013503885A (ja) 2009-09-01 2013-02-04 ノースウェスタン ユニバーシティ 担体としてオリゴヌクレオチド修飾されたナノ粒子を使用する治療薬の送達
WO2011094335A2 (en) 2010-01-26 2011-08-04 Yale University Microrna signatures predicting responsiveness to anti-her2 therapy
EP2834259A4 (en) * 2012-04-02 2016-08-24 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES
MX2014014266A (es) 2012-05-22 2015-06-23 Smith & Nephew Aparatos y metodos para terapia de heridas.
PL2880160T3 (pl) 2012-08-03 2019-03-29 Cedars-Sinai Medical Center Izolowanie wzmacniających transport mutantów białka dostarczającego lek
ES2791043T3 (es) 2013-05-08 2020-10-30 Cedars Sinai Medical Center Orientación de corroles para toxicidad tumoral e IRM
EP3791889B1 (en) 2014-01-17 2024-02-21 Cedars-Sinai Medical Center C-met receptor targeting constructs and uses thereof
CA2943297A1 (en) 2014-04-04 2015-10-08 Cedars-Sinai Medical Center Targeting trastuzumab-resistant her2+ breast cancer with a her3-targeting nanoparticle
AU2015307186A1 (en) 2014-08-27 2017-04-13 Peptimed, Inc. Anti-tumor compositions and methods
CA3025348A1 (en) 2016-05-27 2017-11-30 Cedars-Sinai Medical Center Drug-delivery nanoparticles and treatments for drug-resistant cancer
US20190240344A1 (en) 2016-10-03 2019-08-08 Eos Biosciences, Inc. Functional rna and small-molecule drug therapeutic complexes and nanoparticle delivery vehicles
MX2020006890A (es) 2018-01-02 2020-09-07 Cedars Sinai Medical Center Nanoparticulas para la administracion dirigida de polipeptidos terapeuticos.

Similar Documents

Publication Publication Date Title
JP2017508724A5 (enExample)
Sabit et al. Precision nanomedicine: navigating the tumor microenvironment for enhanced cancer immunotherapy and targeted drug delivery
Chen et al. Tumor-associated-macrophage-membrane-coated nanoparticles for improved photodynamic immunotherapy
Batool et al. A detailed insight of the tumor targeting using nanocarrier drug delivery system
Von Roemeling et al. Breaking down the barriers to precision cancer nanomedicine
Zheng et al. Nanomedicine combats drug resistance in lung cancer
Erel-Akbaba et al. Radiation-induced targeted nanoparticle-based gene delivery for brain tumor therapy
Li et al. Tumor vascular-targeted co-delivery of anti-angiogenesis and chemotherapeutic agents by mesoporous silica nanoparticle-based drug delivery system for synergetic therapy of tumor
Yan et al. Targeted nanomedicine for prostate cancer therapy: docetaxel and curcumin co-encapsulated lipid–polymer hybrid nanoparticles for the enhanced anti-tumor activity in vitro and in vivo
Zhang et al. Advanced applications of DNA nanostructures dominated by DNA origami in antitumor drug delivery
George et al. Advances in nanotechnology-based platforms for survivin-targeted drug discovery
Han et al. Supramolecular engineering of molecular inhibitors in an adaptive cytotoxic nanoparticle for synergistic cancer therapy
Xu et al. Nanomedicine-based adjuvant therapy: a promising solution for lung cancer
Hameed et al. Nanotherapeutic approaches targeting angiogenesis and immune dysfunction in tumor microenvironment
Basingab et al. From pioneering discoveries to innovative therapies: a journey through the history and advancements of nanoparticles in breast cancer treatment
Zhang et al. Management of castrate resistant prostate cancer—recent advances and optimal sequence of treatments
Razzaq et al. Nanomedicine innovations in colon and rectal cancer: advances in targeted drug and gene delivery systems
Wei et al. Cell-and subcellular organelle-targeting nanoparticle-mediated breast cancer therapy
Srinivasan et al. Nanobiomaterials in cancer therapy
Wang et al. Nanoparticle-Mediated immunotherapy in Triple-Negative breast cancer
Cho et al. Multi-functional nanomedicines for combinational cancer immunotherapy that transform cold tumors to hot tumors
Wu et al. Extracellular Vesicle-Based drug delivery systems in cancer therapy
Zeinali et al. Current advances in nanocarriers for cancer therapy
Yalamandala et al. Advancing brain immunotherapy through functional nanomaterials
Wang et al. Current application of nanoparticle drug delivery systems to the treatment of anaplastic thyroid carcinomas